Cargando…
SNF472, a novel inhibitor of vascular calcification, could be administered during hemodialysis to attain potentially therapeutic phytate levels
BACKGROUND: Cardiovascular calcification (CVC) is a major concern in hemodialysis (HD) and the loss of endogenous modulators of calcification seems involved in the process. Phytate is an endogenous crystallization inhibitor and its low molecular mass and high water solubility make it potentially dia...
Autores principales: | Perelló, Joan, Gómez, M., Ferrer, M. D., Rodríguez, N. Y., Salcedo, C., Buades, J. M., Pérez, M. M., Torregrosa, J. V., Martín, E., Maduell, F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829128/ https://www.ncbi.nlm.nih.gov/pubmed/29350348 http://dx.doi.org/10.1007/s40620-018-0471-9 |
Ejemplares similares
-
Characterization of SNF472 pharmacokinetics and efficacy in uremic and non-uremic rats models of cardiovascular calcification
por: Ferrer, Miguel D., et al.
Publicado: (2018) -
Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis — Subgroup Analyses of the CALIPSO Trial
por: Raggi, Paolo, et al.
Publicado: (2020) -
Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification
por: Bellasi, Antonio, et al.
Publicado: (2019) -
The CALCIPHYX study: a randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis
por: Sinha, Smeeta, et al.
Publicado: (2021) -
Relationship between Urinary Level of Phytate and Valvular Calcification in an Elderly Population: A Cross-Sectional Study
por: Fernández-Palomeque, Carlos, et al.
Publicado: (2015)